<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8052">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01677104</url>
  </required_header>
  <id_info>
    <org_study_id>11/SW/0195</org_study_id>
    <secondary_id>1204620</secondary_id>
    <nct_id>NCT01677104</nct_id>
  </id_info>
  <brief_title>The Microvascular Function of GLP-1 and Its Analogues</brief_title>
  <official_title>The Microvascular Function of GLP-1 and Its Analogues in Humans, in Vivo: the Role of DPP-IV Inhibition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katarina Kos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Diabetes UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Devon and Exeter NHS Foundation Trust</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Incretins have become a successful drug target in the repertoire of medications used for the
      treatment of type 2 diabetes. However little is known about a potential benefit of GLP-1 on
      the vascular system in humans, independent of their glucose lowering actions and data are
      only derived from ex vivo studies in animals. Particularly little is known about clinically
      relevant benefits of GLP-1 and its analogues on the microvascular system of individuals with
      type 2 diabetes.

      The vascular effect could be medicated by endogenous GLP-1 (9,36) amide, the breakdown
      product of GLP-1 (7,36) amide which has a low affinity for the GLP-1 receptor. The
      investigators hypothesis is that the co-administration of DPP-IV inhibitors will lack the
      beneficial effects of GLP-1 on the vascular system as GLP-1 (9,36) amide will not be
      produced by the body.

      The study aims to examine the response of GLP-1 and its analogues on small blood vessels
      and examine the effect of  the addition of DPP-IV inhibition in healthy lean individuals,
      obese individuals and subjects with Type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>skin blood flow</measure>
    <time_frame>3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>skin blood flow will be assessed before and after microinjection of GLP-1 or its analogues and the injection site monitored and compared to sites injected with placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>DPP-IV inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Linagliptin 5mg (Tradjenta) before microinjection of GLP-1 and its analogues</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One placebo tablet before microinjection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition</description>
    <arm_group_label>DPP-IV inhibitor</arm_group_label>
    <arm_group_label>Placebo pill</arm_group_label>
    <other_name>native GLP-1(7,36)</other_name>
    <other_name>Exenatide (Byetta)</other_name>
    <other_name>Liraglutide (Vicotza)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>DPP-IV inhibitor</arm_group_label>
    <arm_group_label>Placebo pill</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lean BMI ≤ 25.0 kg/m2

          -  Obese BMI ≥30.0kg/m2

          -  Non diabetic subjects and subjects with Type 2 diabetes on stable medication for at
             least 3 months

        Exclusion Criteria:

          -  cardiovascular disease

          -  Raynaud's disease

          -  current treatment with any anti-hypertensive

          -  lipid lowering therapies

          -  severe hepatic impairment

          -  pregnancy and lactation

          -  subjects with Type 2 diabetes on insulin therapy

          -  subjects with Type 2 diabetes on sulphonylureas

          -  subjects with Type 2 diabetes on incretin based therapies

          -  subjects with Type 2 diabetes and peripheral vascular disease

          -  subjects with Type 2 diabetes and history of advanced retinopathy

          -  subjects with Type 2 diabetes and advanced nephropathy

          -  subjects with Type 2 diabetes with uncontrolled diabetes (HbA1c &gt; 8.5%)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katarina Kos, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institue of Biomedical and Clinical Sciences, Peninsula Medical School, University of Exeter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarina Kos, MD, PHD</last_name>
    <phone>01392406761</phone>
    <email>katarina.kos@pcmd.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kim Gooding, PhD</last_name>
    <phone>01392403081</phone>
    <email>kim.gooding@pcmd.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diabetes and Vascular Center</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Gooding, PhD</last_name>
      <phone>01392403081</phone>
      <email>kim.gooding@pcmd.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Kim Gooding, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Shore, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 18, 2014</lastchanged_date>
  <firstreceived_date>August 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Royal Devon and Exeter NHS Foundation trust</investigator_affiliation>
    <investigator_full_name>Katarina Kos</investigator_full_name>
    <investigator_title>Consultant Physician and Senior Lecturer</investigator_title>
  </responsible_party>
  <keyword>GLP-1</keyword>
  <keyword>DPP-IV inhibitor</keyword>
  <keyword>microcirculation</keyword>
  <keyword>Exenatide</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>Linagliptin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
